Eisai R&d Management Co., Ltd.

Eisai Inc.

Utpal Majumder

Jing Li

Earl Albone

Toshimitsu Uenaka

Xin Cheng

Daniel Custar

Keiji Furuuchi

Sharon McGonigle

Maarten H D Postema

Daniel W Custar

The present invention provides, among other things, compositions and methods relating to detection and/or treatment cancer (e.g., one or more tumors) that expresses Neuropilin 1 (NRP1). The present invention provides methods of treating cancer that include administering a chlorotoxin agent to a subject (e.g., to a subject suffering from or susceptible to the cancer which may, in some embodiments, be a cancer that expresses NRP1). In some embodiments, a chlorotoxin agent for use in accordance with the present invention can be or comprise a chlorotoxin polypeptide and a payload moiety (e.g., as a covalent conjugate).

Chlorotoxin agents and uses thereof

Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.

Eribulin-based antibody-drug conjugates and methods of use

Growing community of inventors

Andover, MA, United States of America

Utpal Majumder